TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must not be or have been on highly active antiretroviral therapy.~* Participants must have a CD4 count greater than 250 cells/mm3.~* Participants must be at least 18 years of age.~* Participants must be able and willing to participate and give written informed consent.~* Participants must be able and willing to return for the scheduled follow-up visits.~* In addition, in order to be included in the treatment phase of the study, patients must have at least one stool specimen positive for a soil transmitted helminth.~Exclusion Criteria:~* Participants who have received treatment for helminth infection in the past 6 months (by self report or chart review).~* Participants must not be pregnant at the time of treatment (by urine HCG testing).~* Participants who present with other serious co-morbidities such as severe anaemia, malaria or tuberculosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Albendazole
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Infant or child aged 1 month to 17 years, who meets clinical criteria for KD according to American Heart Association guidelines (Table 2): Fever (T≥38oC or 100.4oC) ≥ 3 days and ≥ 2 clinical criteria with left anterior descending (LAD)/right coronary artery (RCA) Z score ≥ 3.0 or an aneurysm (≥ 1.5 x the adjacent segment) of one of the coronary artery segments~2. Patient presents within the first 20 days after fever onset~3. Parent or legal guardian able and willing to provide informed consent; adolescent or child assent as appropriate~4. Post-menarchal females: Negative pregnancy test at screening and willing to use two forms of contraception during the study~5. Males engaging in sexual activity that could lead to pregnancy willing to use a condom.~Exclusion Criteria:~1. Use of an IL-1 antagonist within the 3 months prior to enrollment~2. History of chronic disease, except asthma, atopic dermatitis, autism or controlled seizure disorder~3. History of hypersensitivity to anakinra~4. History of tuberculosis (TB) or TB exposure

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): This is a dose escalation study (4 mg/kg, 6 mg/kg and 8 mg/kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fenofibrate Therapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* we included appropriate for gestational age full-term infants with pathological unconjugated hyperbilirubinemia who are candidate for phototherapy according to American academy of pediatrics guidelines~Exclusion Criteria:~* Full term infants with intrauterine growth restriction, congenital malformations, conjugated hyperbilirubinemia, severe jaundice initially required exchange transfusion, skin abrasions or infection, and preterm infants were excluded

- Gender: ALL
- Minimum Age: None
- Maximum Age: 28 Days
- Healthy Volunteers: None

Study Arms:
- GROUP1 (Type: ACTIVE_COMPARATOR): group receiving single dose fenofibrate
- GROUP2 (Type: ACTIVE_COMPARATOR): group receiving double dose fenofibrate
- GROUP3 (Type: PLACEBO_COMPARATOR): photo therapy only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cell Therapy in HFpEF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Preserved left ventricular systolic function on echocardiography (LVEF\>50%)~* Evidence of diastolic dysfunction by echocardiography (E/e'\>15)~* Symptoms of heart failure~* NT-proBNP levels \>300 pg/ml~* absence of permanent atrial fibrillation~Exclusion Criteria:~* acute multi-organ failure~* history of any malignant disease within 5 years~* diminished functional capacity due to non-cardiac co-morbidities (COPD, PAOD, morbid obesity)~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SC Group (Type: EXPERIMENTAL): In Phase 1 of the study, all patients will be treated with optimization of medical therapy for 6 months. Thereafter, all patients will cros over to Phase 2 of the study, where they will receive transendocardial CD34+ cell therapy. Follow-up of Phase 2 will last for 6 months. At the time of enrollment (6 months before cell therapy), at time of cell therapy, and 6 months thereafter we will perform detailed clinical evaluation, laboratory assays, echocardiography, 6-minute walk test, and measure plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.1 or 1.2) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to screening, and migraine onset prior to age 50.~Exclusion Criteria:~* Are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product.~* Current use or prior exposure to Galcanezumab or other antibodies to CGRP or its receptor.~* Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to Galcanezumab and the excipients in the investigational product.~* History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 120 milligrams (mg) Galcanezumab (Type: EXPERIMENTAL): 120 mg galcanezumab (LY2951742) administered subcutaneously (SC) once a month for 6 months.
- 240 mg Galcanezumab (Type: EXPERIMENTAL): 120 mg galcanezumab (LY2951742) administered SC once a month for 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC once a month for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult, prevalent hemodialysis patients~* Informed and consented~* Hemodialysis 3x/week via a tunneled cuffed catheter~* Urokinase administration at least two times during the previous 6 months (with more than a week between 2 administrations)~* Adequate catheter function during the week before inclusion (defined by blood flow more than 250ml/min on each dialysis session and blood flow within 15% of the maximal blood flow after the last Urokinase administration)~Exclusion Criteria:~* Presence of heparin-induced thrombocytopenia~* Major hemorrhage or intracranial bleeding in the previous 3 months~* Pericarditis~* Intolerance to Taurolidine, citrate or to Urokinase~* Active catheter-related infection~* Catheter in the femoral vein

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Taurolidine Urokinase (Type: EXPERIMENTAL): Taurolock Urokinase is used weekly in this arm substituting the classic Taurolock HEP500
- Taurolidine Heparin (Type: ACTIVE_COMPARATOR): Taurolock HEP 500 is used as locking solution after each dialysis session

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 aged or over~* Patients with blood pressure measured at Visit 1; MSSBP≤180mmHg and MSDBP≤110 mmHg if on anti-hypertensive drugs, 160mmHg≤MSSBP≤199mmHg and 80mmHg≤MSDBP≤119mmHg if not on anti-hypertensive drugs~* Patients with blood pressure measured at Visit 2 were 160mmHg≤MSSBP≤199mmHg and 80mmHg≤MSDBP≤119mmHg~Exclusion Criteria:~* Inability to stop all prior anti-hypertensive drugs safely during wash out period of 3 to 7 days~* ≥ sitSBP 20mmHg or ≥ sitDBP 10mmHg of variation in three measurements from the reference arm selected at Screening~* History of hypersensitivity to dihydropyridines, angiotensin II receptor blockers or thiazide diuretics~* Secondary hypertension or suspected to be~* Continuously took medicinal drugs that might affect blood pressure rather than anti-hypertensive drugs more than 3 months~* Type 2 diabetes mellitus which is not controlled or with type 1 diabetes mellitus~* History of severe neurovascular disease, severe heart disease~* Known as moderate or malignant retinopathy.~* Renal diseases; serum creatinine ≥ 2mg/dl~* Hepatic diseases; increase in ALT or AST ≥ 2xUNL~* Anuria~* Hyponatremia/hypokalemia or hypercalcemia~* Active Gout~* Surgical or medical diseases which might significantly change ADME of medicines~* History of malignant tumor~* Autoimmune diseases~* History of alcohol or drug abuse~* Positive to pregnancy test, nursing mother, woman with an intention of pregnancy~* Considered inappropriate to participate in the clinical trial with any reason, based on investigator's decision~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- amlodipine/losartan (Type: EXPERIMENTAL): None
- amlodipine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged18 years and older.~* Histologically proven malignant solid tumors who were receiving their second, third or fourth line of palliative chemotherapy and who showed at the second or third course progressive disease as their maximum response according to the RECIST criteria or to the IGCG CA125 criteria in case of ovarian cancer patients.~* Measurable disease defined by 1 of the following criteria: Any unidimensional measurable lesion ≥ 10 mm by standard MRI or CT scan for solid tumors; or at least 1 non-measurable lesion that is evaluable by nuclear medicine, tumor markers, or other reliable measures.~* Eastern Cooperative Oncology Group (ECOG) performance status ≤2; Absolute leukocyte count (≥4000/mm3), platelets ≥100,000/mm3, hemoglobin ≥9.0 g/dL; total bilirubin, aspartate amino transferase (AST) and alanine amino transferase (ALT) \<1.5 the upper normal limit (UNL), creatinine ≤1.2 mg/dL or a calculated creatinine clearance of ≥60 mL/min.~* Life expectancy of more than three months,~* Written informed consent.~Exclusion Criteria:~* History of allergy to hydralazine or valproate.~* Past or present condition of rheumatic disease, central nervous system disease, heart failure from aortic stenosis and postural hypotension as diagnosed by a physician.~* Previous use of the experimental drugs (hydralazine and magnesium valproate)~* Pregnancy or breast-feeding.~* Uncontrolled systemic disease or infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, 5-17 years of age~* Subjects must have a DSM-IV diagnosis of a bipolar spectrum disorder (type I, II, or Not Otherwise Specified) and currently display mixed, manic, or hypomanic symptoms (without psychotic features) according to clinical assessment based on the DSM-IV and confirmed with structured diagnostic interview~* Subjects and their legal representative must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator and to cooperate with all tests and examinations required by the protocol~* Subjects and their legal representatives must be considered reliable.~* Each subject and his/her authorized legal representative must understand the nature of the study. The subject's authorized legal representative must provide written consent and the subject must provide written assent.~* Subjects must have an initial score on the YMRS of at least 15.~Exclusion Criteria:~* Investigator and his/her immediate family (defined as the investigator's spouse, parent, child, grandparent, or grandchild)~* Serious or unstable illness including hepatic, rental, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease~* Uncorrected hypothyroidism or hyperthyroidism~* History of sensitivity to N-acetylcysteine, a history of intolerance to N-acetylcysteine, or a non-responder after 2 months of treatment at adequate doses as determined by the clinician~* Severe allergies or multiple adverse drug reactions~* Current or past history of seizures~* Active substance abusers, per clinician judgment~* Judged clinically to be at serious suicidal risk~* Current diagnosis of schizophrenia~* Pregnancy~* C-SSRS score ≥ 4~* IQ \< 70

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Open-label Treatment with NAC (Type: EXPERIMENTAL): 12-week, open-label treatment with NAC. Subjects will be treated with the following dose:~Subjects ages 5-12:~Week 1: 900mg po daily Weeks 2+: 900mg po QAM, 900mg po QPM~Subjects ages 13-17:~Week 1: 900mg po daily Weeks 2-3: 900mg po QAM, 900mg po QPM Weeks 4+: 1800mg po QAM, 900mg po QPM~In Weeks 3-12 for subjects ages 13-17, we will encourage twice per day dosing, but we will permit daily dosing if needed for adherence.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Autoregulation Monitoring During Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients undergoing primary or re-operative Coronary Artery Bypass Graft (CABG) and/or valvular surgery or ascending aorta surgery that requires Cardio-pulmonary bypass (CPB) who are at high risk for neurologic complications (stroke or encephalopathy) as determined by a Johns Hopkins risk score of \>0.02~Exclusion Criteria:~* Contraindication to MRI imaging (e.g., permanent pacemaker, cerebral arterial vascular clips)~* Liver function test before surgery more than twice the upper limit of institutional normal~* Pre-existing renal dysfunction defined as an estimated glomerular filtration rate of ≤60 mL/min, or current renal dialysis~* Emergency surgery~* Inability to attend outpatient visits~* Visual impairment or inability to speak and read English. The patient will be excluded from further study if an adequate temporal window for Transcranial Doppler (TCD) monitoring can not be identified before surgery.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Blood pressure targets during cardiopulmonary bypass based on institutional standards of empiric management.
- Intervention (Type: EXPERIMENTAL): Blood pressure management based on cerebral autoregulation data.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Cancer patient with metastatic or locally advanced solid tumor of lung, pancreas, stomach, colon/rectum, bladder or ovary initiating a (new) course of chemotherapy with a minimum intent of 3 months therapy~Exclusion Criteria:~* Required systematic venous thromboprophylaxis or curative treatment with anti-coagulant or thrombolytic;~* High risk of bleeding;~* Severe renal impairment (estimated creatinine clearance \<30 mL/min);~* ECOG (Eastern Cooperative Oncology Group) performance status 3 \& 4;~* Major surgery within 4 weeks before randomization;~* Known hypersensitivity to unfractionated heparin \[UFH\] or low molecular weight heparin \[LMWH\].~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semuloparin (Type: EXPERIMENTAL): Semuloparin sodium 20 mg once daily until change in chemotherapy regimen
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for semuloparin) once daily until change in chemotherapy regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Effects of Bolus of Ketamine Versus Fentanyl in Patients With Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (\>18 years) patients.~* With septic shock on vasopressor therapy~* Mechanically ventilated~* Need for sedation~Exclusion Criteria:~* Hemodynamic instability (MAP \<65 mmHg) despite appropriate volume replacement and vasopressor therapy~* Noradrenaline infusion rate \<0.05 mcg/kg/min~* Poor cardiac window on the ultrasound.~* Known allergy to study drugs~* Neurocritical patients with signs of increased intracranial tension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine group (Type: ACTIVE_COMPARATOR): bolus of sedation for resuming sedation after sedation vacation
- Fentanyl group (Type: ACTIVE_COMPARATOR): bolus of sedation for resuming sedation after sedation vacation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Efficacy and Safety of 'URSA SOFT CAP. (UDCA-003)' in Fatigue Patients With Liver Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CIS greater than or equal to 76, HADS less than or equal to 10~* ALT greater than upper limit of normal OR fatty liver on US~Exclusion Criteria:~* Subjects who have diseases that can cause fatigue~* Subjects who are taking medication that can cause fatigue

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- udca003 (Type: EXPERIMENTAL): udca003
- placebo (Type: PLACEBO_COMPARATOR): placebo of udca003

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete